Trade Summary

Yesterday, Sethuraman Natarajan, serving as Pres, Research, Develop. at Entrada Therapeutics, Inc. (TRDA), sold 25,907 shares at $15.39 per share, for a total transaction value of $398,810.00. Following this transaction, Sethuraman Natarajan now holds 216,317 shares of TRDA.

This sale represents a 11.00% decrease in Sethuraman Natarajan's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, May 4, 2026 and publicly disclosed via SEC Form 4 filing on Monday, May 4, 2026, meaning the disclosure happened on the same day as the trade.

Entrada Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.